The aim of this study was to determine if patients positive for EGFR mutations who were taking first-line EGFR-TKIs experienced a reversal of the poor outcomes of NSCLC patients with de novo bone metastases. This evidence concerns the gene EGFR and non-small cell lung carcinoma.